Vigano O - Search Results

1

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.

Bonora S, Calcagno A, Vigano O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G, Rusconi S. Bonora S, et al. Among authors: vigano o. Curr HIV Res. 2014;12(5):339-46. doi: 10.2174/1570162x12666140807151616. Curr HIV Res. 2014. PMID: 25106410

2

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Bonora S, et al. Among authors: vigano o. J Antimicrob Chemother. 2015 Nov;70(11):3096-9. doi: 10.1093/jac/dkv208. Epub 2015 Jul 14. J Antimicrob Chemother. 2015. PMID: 26174719 Free article. Clinical Trial.

3

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.

Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Gonzalez de Requena D, et al. Among authors: vigano o. J Antimicrob Chemother. 2011 Jan;66(1):192-200. doi: 10.1093/jac/dkq384. Epub 2010 Oct 29. J Antimicrob Chemother. 2011. PMID: 21037251 Free article.

4

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

Ortu M, Vitiello P, Adorni F, Rossotti R, Di Vincenzo P, Vigano O, Galli M, Rusconi S. Ortu M, et al. Among authors: vigano o. Curr HIV Res. 2011 Dec 1;9(8):625-9. doi: 10.2174/157016211798998790. Curr HIV Res. 2011. PMID: 22211659 Free article.

5

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

Ferraris L, Viganò O, Peri A, Tarkowski M, Milani G, Bonora S, Adorni F, Gervasoni C, Clementi E, Di Perri G, Galli M, Riva A. Ferraris L, et al. Among authors: vigano o. J Antimicrob Chemother. 2012 Sep;67(9):2236-42. doi: 10.1093/jac/dks175. Epub 2012 Jun 2. J Antimicrob Chemother. 2012. PMID: 22661571 Clinical Trial.

6

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

Rusconi S, Giacomet V, Mameli C, Viganò A, Viganò O, Adorni F, Galli M, Zuccotti GV. Rusconi S, et al. Among authors: vigano a, vigano o. BMC Infect Dis. 2012 Aug 6;12:179. doi: 10.1186/1471-2334-12-179. BMC Infect Dis. 2012. PMID: 22866946 Free PMC article.

7

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.

Vergani B, Cicero ML, Vigano' O, Sirianni F, Ferramosca S, Vitiello P, Di Vincenzo P, Pia De Pasquale M, Galli M, Rusconi S. Vergani B, et al. Among authors: vigano o. J Clin Virol. 2008 Feb;41(2):154-9. doi: 10.1016/j.jcv.2007.10.003. Epub 2007 Nov 19. J Clin Virol. 2008. PMID: 18024202 Free article.

8

Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.

Bulgheroni E, Croce F, Citterio P, Viganò O, Visonà R, Sala E, Galli M, Rusconi S. Bulgheroni E, et al. Among authors: vigano o. J Clin Virol. 2004 Jan;29(1):27-32. doi: 10.1016/s1386-6532(03)00082-9. J Clin Virol. 2004. PMID: 14675866

9

Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

Bulgheroni E, Citterio P, Croce F, Lo Cicero M, Viganò O, Soster F, Chou TC, Galli M, Rusconi S. Bulgheroni E, et al. Among authors: vigano o. J Antimicrob Chemother. 2004 Mar;53(3):464-8. doi: 10.1093/jac/dkh103. Epub 2004 Feb 12. J Antimicrob Chemother. 2004. PMID: 14963061

10

Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.

Gervasoni C, Vigano O, Grinelli E, Ortu M, Galli M, Rusconi S. Gervasoni C, et al. Among authors: vigano o. AIDS Patient Care STDS. 2007 Jan;21(1):1-3. doi: 10.1089/apc.2006.0056. AIDS Patient Care STDS. 2007. PMID: 17263652

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters